Recro Pharma, Inc. (NASDAQ:REPH) Files An 8-K Other Events
Item8.01
| Other Events. |
On June8, 2017, Recro Pharma, Inc. (the Company) updated its
corporate presentation, which is attached as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by
reference. Representatives of the Company will use the updated
presentation in various meetings with investors from time to
time.
| Item9.01 | Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Document |
|
| 99.1 | Investor presentation of Recro Pharma, Inc. |
About Recro Pharma, Inc. (NASDAQ:REPH)
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.